Santen’s Tapros Mini For Glaucoma And Ocular Hypertension Approved
This article was originally published in PharmAsia News
Santen Pharmaceuticals received approval for their preservative-free ophthalmic solution Tapros Mini (tafluprost) for the treatment of glaucoma and ocular hypertension.
You may also be interested in...
Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.
Potentially transformative treatments for severe asthma, COPD and osteoarthritis are among some of the below-the-radar projects the Swiss major is advancing, according to Vas Narasimhan.
Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.